Drugs / TICE®-strain BCG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00070070 | Oct 2003 → Jan 2006 | transitional cell carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TICE-strain BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00070070 ↗ |
| Known as | Bacille Calmette Guerin | “Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the immune system and stop tumor cells from growing.” NCT00070070 ↗ |
| Modality | Vaccine | “BCG Vaccine” NCT00070070 ↗ |